Related Experiment Videos
Infliximab for peristomal pyoderma gangrenosum.
D Mimouni1, G J Anhalt, D J Kouba
1Department of Dermatology, Johns Hopkins University School of Medicine, 720 Rutland Ave, Ross Building, Suite 771, Baltimore, MD 21205, USA.
The British Journal of Dermatology
|May 20, 2003
Summary
Peristomal pyoderma gangrenosum (PPG), a challenging skin condition, showed significant improvement with infliximab treatment. This study suggests infliximab is a safe and effective option for managing PPG, especially when associated with inflammatory bowel disease.
Area of Science:
- Dermatology
- Gastroenterology
- Immunology
Background:
- Peristomal pyoderma gangrenosum (PPG) is a severe, treatment-resistant variant of pyoderma gangrenosum (PG).
- PPG presents a significant therapeutic challenge due to its refractory nature and associated morbidity.
- Inflammatory bowel disease (IBD) is often associated with PPG, complicating patient management.
Observation:
- Infliximab, a tumor necrosis factor-alpha inhibitor, is established for IBD and rheumatoid arthritis.
- Limited data exists on infliximab's efficacy in treating pyoderma gangrenosum, particularly PPG.
- This study reports on three patients with IBD-associated PPG treated with infliximab.
Findings:
- All three patients tolerated infliximab without significant adverse events.
- Two patients achieved complete remission of PPG following infliximab administration.
- One patient experienced a partial response to infliximab therapy.
Implications:
- Infliximab demonstrates potential as a safe and effective treatment for peristomal pyoderma gangrenosum.
- These findings support further investigation into TNF-alpha inhibitors for refractory PPG.
- This offers a promising therapeutic avenue for patients suffering from IBD-associated PPG.